全文获取类型
收费全文 | 62829篇 |
免费 | 3454篇 |
国内免费 | 222篇 |
专业分类
耳鼻咽喉 | 873篇 |
儿科学 | 3871篇 |
妇产科学 | 1269篇 |
基础医学 | 7250篇 |
口腔科学 | 1638篇 |
临床医学 | 3988篇 |
内科学 | 12317篇 |
皮肤病学 | 1805篇 |
神经病学 | 3845篇 |
特种医学 | 1911篇 |
外科学 | 9203篇 |
综合类 | 1994篇 |
一般理论 | 32篇 |
预防医学 | 3128篇 |
眼科学 | 2539篇 |
药学 | 5986篇 |
中国医学 | 471篇 |
肿瘤学 | 4385篇 |
出版年
2023年 | 428篇 |
2022年 | 460篇 |
2021年 | 1973篇 |
2020年 | 1302篇 |
2019年 | 1554篇 |
2018年 | 2096篇 |
2017年 | 1494篇 |
2016年 | 1901篇 |
2015年 | 1873篇 |
2014年 | 2831篇 |
2013年 | 3334篇 |
2012年 | 4666篇 |
2011年 | 4733篇 |
2010年 | 2796篇 |
2009年 | 2226篇 |
2008年 | 3316篇 |
2007年 | 3346篇 |
2006年 | 3150篇 |
2005年 | 2804篇 |
2004年 | 2603篇 |
2003年 | 2171篇 |
2002年 | 1899篇 |
2001年 | 1428篇 |
2000年 | 1368篇 |
1999年 | 1111篇 |
1998年 | 451篇 |
1997年 | 347篇 |
1996年 | 312篇 |
1995年 | 330篇 |
1994年 | 270篇 |
1993年 | 232篇 |
1992年 | 712篇 |
1991年 | 685篇 |
1990年 | 676篇 |
1989年 | 641篇 |
1988年 | 559篇 |
1987年 | 479篇 |
1986年 | 459篇 |
1985年 | 452篇 |
1984年 | 339篇 |
1983年 | 251篇 |
1982年 | 138篇 |
1981年 | 160篇 |
1979年 | 264篇 |
1978年 | 168篇 |
1977年 | 167篇 |
1975年 | 138篇 |
1974年 | 152篇 |
1973年 | 150篇 |
1972年 | 165篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Microbial co-infections are another primary concern in patients with coronavirus disease 2019 (COVID-19), yet it is an untouched area among researchers. Preliminary data and systematic reviews only show the type of pathogens responsible for that, but its pathophysiology is still unknown. Studies show that these microbial co-infections are hospital-acquired/nosocomial infections, and patients admitted to intensive care units with invasive mechanical ventilation are highly susceptible to it. Patients with COVID-19 had elevated inflammatory cytokines and a weakened cell-mediated immune response, with lower CD4+ T and CD8+ T cell counts, indicating vulnerability to various co-infections. Despite this, there are only a few studies that recommend the management of co-infections. 相似文献
2.
3.
Apoorva Challa Neeraj Mahajan Seema Sood Arti Kapil Bimal Kumar Das Vishnubhatla Sreenivas Somesh Gupta 《Indian journal of medical microbiology》2022,40(3):433-435
Treatment guidelines for management of uncomplicated gonorrhoeae have been recently modified owing to alarming upsurge in azithromycin resistance. This study investigated the prevalence and genetic determinants of gonococcal azithromycin resistance in India. Four (5.7%) of 70 gonococcal isolates were resistant to azithromycin. Of 16 isolates investigated for molecular mechanisms of resistance, 13 (81.3%) and 6 (37.5%) isolates exhibited mutations in coding and promoter regions of mtrR gene, respectively. However, ermA, ermB and ermC genes or mutations in rrl gene were absent in all isolates. Azithromycin resistance is low in India posing no immediate threat to use of dual-therapy for syndromic management. 相似文献
4.
5.
6.
Rajiv V. Dave Baek Kim Alona Courtney Rachel OConnell Tim Rattay Vicky P. Taxiarchi Jamie J. Kirkham Elizabeth M. Camacho Patricia Fairbrother Nisha Sharma Christopher W. J. Cartlidge Kieran Horgan Stuart A. McIntosh Daniel R. Leff Raghavan Vidya Shelley Potter Chris Holcombe Ellen Copson Charlotte E. Coles Ramsey I. Cutress Ashu Gandhi Cliona C. Kirwan 《British journal of cancer》2021,124(11):1785
Background The B-MaP-C study aimed to determine alterations to breast cancer (BC) management during the peak transmission period of the UK COVID-19 pandemic and the potential impact of these treatment decisions.Methods This was a national cohort study of patients with early BC undergoing multidisciplinary team (MDT)-guided treatment recommendations during the pandemic, designated ‘standard’ or ‘COVID-altered’, in the preoperative, operative and post-operative setting.Findings Of 3776 patients (from 64 UK units) in the study, 2246 (59%) had ‘COVID-altered’ management. ‘Bridging’ endocrine therapy was used (n = 951) where theatre capacity was reduced. There was increasing access to COVID-19 low-risk theatres during the study period (59%). In line with national guidance, immediate breast reconstruction was avoided (n = 299). Where adjuvant chemotherapy was omitted (n = 81), the median benefit was only 3% (IQR 2–9%) using ‘NHS Predict’. There was the rapid adoption of new evidence-based hypofractionated radiotherapy (n = 781, from 46 units). Only 14 patients (1%) tested positive for SARS-CoV-2 during their treatment journey.Conclusions The majority of ‘COVID-altered’ management decisions were largely in line with pre-COVID evidence-based guidelines, implying that breast cancer survival outcomes are unlikely to be negatively impacted by the pandemic. However, in this study, the potential impact of delays to BC presentation or diagnosis remains unknown.Subject terms: Breast cancer, Surgical oncology, Health care economics, Quality of life, Health policy 相似文献
7.
8.
9.
10.